HTI 1066Alternative Names: HTI-1066
Latest Information Update: 18 Jan 2018
Price : *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Dec 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (unspecified route) (NCT03398720)